Novo Nordisk

Novo Nordisk, a Danish pharmaceutical giant, has built a formidable reputation by focusing on some of the world's most pressing chronic health challenges, particularly diabetes and obesity. Since its inception in 1923, born from the merger of two pioneering Danish companies, Novo Nordisk has been at the forefront of developing innovative treatments. The company's global reach is extensive, operating in 168 countries and employing a dedicated workforce of over 48,000 people. Its headquarters remain in Bagsværd, Denmark, a testament to its deep Danish roots.

The company's commitment extends beyond just product development. Novo Nordisk is widely recognized for its dedication to sustainability, even being named the world's most sustainable company by Corporate Knights in 2012. This focus on responsible business practices, combined with its market leadership in critical therapeutic areas, has translated into significant financial success. By 2023, Novo Nordisk's market value had surpassed Denmark's entire gross domestic product, solidifying its position as Europe's most valuable company. With net sales reaching approximately $42.121 billion in 2024, Novo Nordisk continues to be a major force in global health.[edit]